Supply Chain Truce In COVID-19: Will It Carry Over When Rx Price Debate Resumes?
Manufacturers, insurers, pharmacies and PBMs are united in trying to assure ongoing access to medicines amid the COVID-19 outbreak. Will making common cause in a national emergency mean a more cooperative approach to addressing US drug pricing concerns when normalcy returns?
You may also be interested in...
After failing to get many co-pay waivers in earlier coronavirus relief legislation, the House tries again – with an even bolder ask covering more Americans. The bill would also speed up CDC’s guidance on vaccines and ensure Medicare Part D plans cover all coronavirus treatments. But its not clear whether the Senate will get on board.
The former BARDA director’s whistleblower complaint says he recommended the US government purchase all existing remdesivir doses and set up US-based manufacturing.
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.